Jun, 06, 2022

Soleo Health Named to Genentech’s Limited Drug Distribution Network for Provision of ENSPRYNG®

Company to Distribute FDA-Approved Treatment for Neuromyelitis Optica Spectrum Disorder

FRISCO, Texas, June 6, 2022 – Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been named a limited distribution drug partner for ENSPRYNG® (satralizumab-mwge), manufactured by Genentech, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with severe and life-threatening diseases.

Soleo Health now provides ENSPYRNG to patients with Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune disease of the optic nerve, brain and spinal cord, who are anti-aquaporin-4 (AQP4) antibody positive. ENSPYRNG, a Food & Drug Administration-approved subcutaneous treatment, is administered by patients or caregivers every four weeks. ENSPRYNG is a different kind of treatment in that it is the first and only approved NMOSD therapeutic designed to block the action of interleukin 6 (IL-6)—a protein that may play a vital role in this chronic condition.

Soleo Health’s extensive expertise in providing care for patients – particularly those targeted at treating rare or ultra-rare diseases – makes the Company an appropriate and experienced candidate to bring ENSPRYNG to patients.

Furthermore, Soleo Health’s proprietary clinical outcomes program, SoleMetrics®, which collects and produces valuable real-world data over time, will gather intelligent outcomes from patients throughout their ENSPRYNG journeys to provide clinical and economic value to key stakeholders.

“We continue to forge integral, strong limited distribution partnerships with pharmaceutical manufacturers to aid in advancing the distribution and administration of many proven therapies. In turn, our drug manufacturer partners find our services, clinical care and data highly advantageous to improving patient care,” said Drew Walk, Soleo Health chief executive officer.

About Soleo Health

Soleo Health is an innovative national provider of complex specialty pharmacy services administered in the home or at alternate sites of care. Soleo Health’s interdisciplinary clinical team comprises highly experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. The Company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences.

Soleo Health operates 21 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission.

Visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and Twitter for more information.